Literature DB >> 20008062

A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis.

Gaetano Serviddio1, Francesco Bellanti, Anna Maria Giudetti, Gabriele Vincenzo Gnoni, Antonio Petrella, Rosanna Tamborra, Antonino Davide Romano, Tiziana Rollo, Gianluigi Vendemiale, Emanuele Altomare.   

Abstract

Mitochondrial dysfunction and oxidative stress are determinant events in the pathogenesis of nonalcoholic steatohepatitis. Silybin has shown antioxidant, anti-inflammatory, and antifibrotic effects in chronic liver disease. We aimed to study the effect of the silybin-phospholipid complex (SILIPHOS) on liver redox balance and mitochondrial function in a dietary model of nonalcoholic steatohepatitis. To accomplish this, glutathione oxidation, mitochondrial oxygen uptake, proton leak, ATP homeostasis, and H(2)O(2) production rate were evaluated in isolated liver mitochondria from rats fed a methionine- and choline-deficient (MCD) diet and the MCD diet plus SILIPHOS for 7 and 14 weeks. Oxidative proteins, hydroxynonenal (HNE)- and malondialdehyde (MDA)-protein adducts, and mitochondrial membrane lipid composition were also measured. Treatment with SILIPHOS limited glutathione depletion and mitochondrial H(2)O(2) production. Moreover, SILIPHOS preserved mitochondrial bioenergetics and prevented mitochondrial proton leak and ATP reduction. Finally, SILIPHOS limited the formation of HNE- and MDA-protein adducts. In conclusion, SILIPHOS is effective in preventing severe oxidative stress and preserving hepatic mitochondrial bioenergetics in nonalcoholic steatohepatitis induced by the MCD diet. The modifications of mitochondrial membrane fatty acid composition induced by the MCD diet are partially prevented by SILIPHOS, conferring anti-inflammatory and antifibrotic effects. The increased vulnerability of lipid membranes to oxidative damage is limited by SILIPHOS through preserved mitochondrial function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008062     DOI: 10.1124/jpet.109.161612

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Experimental models of non-alcoholic fatty liver disease in rats.

Authors:  Otto Kucera; Zuzana Cervinkova
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.

Authors:  Ignazio Grattagliano; Catia V Diogo; Maria Mastrodonato; Ornella de Bari; Michele Persichella; David Q H Wang; Adriana Liquori; Domenico Ferri; Maria Rosaria Carratù; Paulo J Oliveira; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

4.  Intrauterine growth retardation increases the susceptibility of pigs to high-fat diet-induced mitochondrial dysfunction in skeletal muscle.

Authors:  Jingbo Liu; Daiwen Chen; Ying Yao; Bing Yu; Xiangbing Mao; Jun He; Zhiqing Huang; Ping Zheng
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

Review 5.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

Review 6.  Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.

Authors:  Yue Ye Huang; Aaron M Gusdon; Shen Qu
Journal:  Lipids Health Dis       Date:  2013-11-09       Impact factor: 3.876

Review 7.  Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects.

Authors:  Ravirajsinh Jadeja; Ranjitsinh V Devkar; Srinivas Nammi
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-03       Impact factor: 2.629

Review 8.  Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects.

Authors:  Ming Hong; Sha Li; Hor Yue Tan; Ning Wang; Sai-Wah Tsao; Yibin Feng
Journal:  Int J Mol Sci       Date:  2015-12-02       Impact factor: 5.923

9.  Silymarin prevents acetaminophen-induced hepatotoxicity in mice.

Authors:  Zuzana Papackova; Marie Heczkova; Helena Dankova; Eva Sticova; Alena Lodererova; Lenka Bartonova; Martin Poruba; Monika Cahova
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

10.  Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.

Authors:  Federico Salomone; Ignazio Barbagallo; Justyna Godos; Vincenzo Lembo; Walter Currenti; Diana Cinà; Roberto Avola; Nicolantonio D'Orazio; Filomena Morisco; Fabio Galvano; Giovanni Li Volti
Journal:  Nutrients       Date:  2017-09-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.